Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ath – page 72

1 642 clinical trials in Ath, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ath at a glance
1 642
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 642 trials in Ath

Open in trial search

Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Migraine+3

Not recruiting

Study Comparing Atogepant and Topiramate for Preventive Treatment in Adults with Migraine

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Sjogren's syndrome

Not recruiting

Safety Study of Efgartigimod in Adults with Primary Sjögren's Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Macrogenics Inc.

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Gout

Not recruiting

Study on the Effects of Tigulixostat and Allopurinol in Patients with Gout and High Uric Acid Levels

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:LG Chem Ltd.

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ath

What the registry says about research in the country

01 Cardiovascular and Cerebrovascular Research

Clinical research in Ath addresses critical cardiovascular conditions, particularly focusing on cerebrovascular events. Investigations center on acute ischemic stroke and high-risk transient ischemic attack, conditions that represent significant causes of disability and mortality. These studies aim to evaluate novel therapeutic approaches designed to reduce the risk of recurrent ischemic events in patients who have experienced these serious cerebrovascular incidents.

  • Assessment of innovative pharmacological interventions for stroke prevention
  • Evaluation of treatment strategies to minimize recurrent cerebrovascular events
  • Investigation of therapeutic efficacy in acute cerebrovascular conditions
  • Research focused on improving outcomes for patients with transient ischemic attacks

The research underway seeks to establish safer and more effective treatment protocols for individuals at elevated risk of stroke, potentially improving long-term neurological outcomes and quality of life for affected patients.

02 Oncology and Gastrointestinal Cancer Research

Ath hosts clinical investigations in the field of oncology, with particular emphasis on gastrointestinal malignancies. Research efforts concentrate on locally advanced rectal cancer, examining treatment strategies tailored to specific patient populations. These trials explore different approaches to neoadjuvant therapy, which involves treatment administered before surgical intervention, aiming to optimize the balance between treatment effectiveness and patient safety.

  • Comparison of conventional neoadjuvant therapy versus total neoadjuvant therapy approaches
  • Evaluation of treatment efficacy and safety profiles in older cancer populations
  • Investigation of optimal timing and sequencing of chemotherapy and radiation therapy
  • Research on personalized treatment strategies for rectal cancer management

These studies are particularly significant as they address the unique needs of older patients with rectal cancer, seeking to identify treatment regimens that maximize therapeutic benefit while minimizing adverse effects in this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.